Compare Stocks: ALEC, MNPR, CLYM, and AURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.78 -2.7%	$1.68	$1.09 ▼ $3.40	$203.18M	0.6	740,527 shs	1.25 million shs
AURA Aura Biosciences	$7.99 +3.5%	$6.93	$4.73 ▼ $9.53	$798.53M	0.4	388,606 shs	538,274 shs
CLYM Climb Bio	$14.00	$12.36	$1.54 ▼ $14.53	$801.68M	0.08	1.07 million shs	910,257 shs
MNPR Monopar Therapeutics	$119.21 -0.8%	$90.83	$29.18 ▼ $124.82	$805.29M	1.47	299,624 shs	223,298 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	-2.73%	+17.88%	-2.73%	-15.24%	+24.48%
AURA Aura Biosciences	+3.50%	+13.98%	+10.21%	-4.88%	+16.81%
CLYM Climb Bio	0.00%	+17.65%	+3.17%	+23.13%	+700.00%
MNPR Monopar Therapeutics	-0.83%	+10.02%	+20.09%	+87.50%	+193.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.78 -2.7%	$1.68	$1.09 ▼ $3.40	$203.18M	0.6	740,527 shs	1.25 million shs
AURA Aura Biosciences	$7.99 +3.5%	$6.93	$4.73 ▼ $9.53	$798.53M	0.4	388,606 shs	538,274 shs
CLYM Climb Bio	$14.00	$12.36	$1.54 ▼ $14.53	$801.68M	0.08	1.07 million shs	910,257 shs
MNPR Monopar Therapeutics	$119.21 -0.8%	$90.83	$29.18 ▼ $124.82	$805.29M	1.47	299,624 shs	223,298 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	-2.73%	+17.88%	-2.73%	-15.24%	+24.48%
AURA Aura Biosciences	+3.50%	+13.98%	+10.21%	-4.88%	+16.81%
CLYM Climb Bio	0.00%	+17.65%	+3.17%	+23.13%	+700.00%
MNPR Monopar Therapeutics	-0.83%	+10.02%	+20.09%	+87.50%	+193.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.13	Hold	$3.63	103.65% Upside
AURA Aura Biosciences	2.25	Hold	$20.50	156.57% Upside
CLYM Climb Bio	3.00	Buy	$22.75	62.50% Upside
MNPR Monopar Therapeutics	3.07	Buy	$112.08	-5.98% Downside

Current Analyst Ratings Breakdown

Latest ALEC, MNPR, CLYM, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CLYM Climb Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $25.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Moderate Buy	$23.00
7/31/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/27/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$17.00 ➝ $20.00
7/23/2026	MNPR Monopar Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$125.00
7/22/2026	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$105.00 ➝ $125.00
7/17/2026	CLYM Climb Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	MNPR Monopar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/14/2026	AURA Aura Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$21.05M	9.39	N/A	N/A	$0.28 per share	6.36
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.16 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.19	N/A	N/A	N/A	-850.13%	-358.06%	-40.71%	N/A
AURA Aura Biosciences	-$106.19M	-$1.74	N/A	N/A	N/A	N/A	-78.12%	-64.08%	8/12/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.78	N/A	N/A	N/A	N/A	-35.60%	-34.41%	N/A
MNPR Monopar Therapeutics	-$13.72M	-$1.90	N/A	N/A	N/A	N/A	-12.84%	-12.57%	8/11/2026 (Estimated)

Latest ALEC, MNPR, CLYM, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6553	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
5/21/2026	Q1 2026	AURA Aura Biosciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A
5/14/2026	Q1 2026	MNPR Monopar Therapeutics	-$0.8703	-$0.46	+$0.4103	-$0.46	N/A	N/A
5/11/2026	Q1 2026	AURA Aura Biosciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.25	5.25
AURA Aura Biosciences	N/A	7.09	7.09
CLYM Climb Bio	N/A	27.86	27.86
MNPR Monopar Therapeutics	N/A	56.04	56.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
AURA Aura Biosciences	96.75%
CLYM Climb Bio	69.76%
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
AURA Aura Biosciences	1.90%
CLYM Climb Bio	2.60%
MNPR Monopar Therapeutics	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	111.03 million	101.81 million	Optionable
AURA Aura Biosciences	50	103.44 million	101.42 million	Not Optionable
CLYM Climb Bio	9	57.26 million	55.77 million	N/A
MNPR Monopar Therapeutics	10	6.70 million	6.05 million	Not Optionable

ALEC, MNPR, CLYM, and AURA Headlines

Recent News About These Companies

Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen

August 8 at 2:11 AM | marketbeat.com

Bank of New York Mellon Corp Has $4.31 Million Position in Monopar Therapeutics Inc. $MNPR

August 7 at 3:03 AM | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year High - What's Next?

August 6 at 10:59 AM | marketbeat.com

Monopar Therapeutics (MNPR) Projected to Post Earnings on Tuesday

August 4, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Reaches New 52-Week High - What's Next?

July 31, 2026 | marketbeat.com

Monopar Therapeutics Inc. $MNPR Position Increased by ADAR1 Capital Management LLC

July 29, 2026 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Rating of "Buy" by Analysts

July 28, 2026 | americanbankingnews.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Analysts

July 28, 2026 | marketbeat.com

HC Wainwright Has Positive Outlook of MNPR FY2027 Earnings

July 24, 2026 | marketbeat.com

Siren L.L.C. Increases Stake in Monopar Therapeutics Inc. $MNPR

July 24, 2026 | marketbeat.com

Walleye Capital LLC Takes Position in Monopar Therapeutics Inc. $MNPR

July 24, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 8.9% - What's Next?

July 23, 2026 | marketbeat.com

HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price

July 22, 2026 | marketbeat.com

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

July 22, 2026 | globenewswire.com

Monopar Therapeutics (NASDAQ:MNPR) Sets New 12-Month High - What's Next?

July 20, 2026 | marketbeat.com

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

July 20, 2026 | globenewswire.com

Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)

July 17, 2026 | seekingalpha.com

Monopar Therapeutics (NASDAQ:MNPR) Shares Up 6.8% - What's Next?

July 15, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Zacks Research

July 15, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Lowered to "Sell" Rating by Wall Street Zen

July 12, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Hits New 12-Month High - Here's Why

July 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, MNPR, CLYM, and AURA Company Descriptions

Alector NASDAQ:ALEC

$1.78 -0.05 (-2.73%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.78 -0.01 (-0.28%)

As of 08/7/2026 07:34 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Aura Biosciences NASDAQ:AURA

$7.99 +0.27 (+3.50%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$8.15 +0.16 (+2.00%)

As of 08/7/2026 07:34 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Climb Bio NASDAQ:CLYM

$14.00 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$13.72 -0.28 (-2.00%)

As of 08/7/2026 07:44 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Monopar Therapeutics NASDAQ:MNPR

$119.21 -1.00 (-0.83%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$119.04 -0.17 (-0.15%)

As of 08/7/2026 07:34 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, MNPR, CLYM, and AURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, MNPR, CLYM, and AURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, MNPR, CLYM, and AURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, MNPR, CLYM, and AURA Company Descriptions

Alector NASDAQ:ALEC

Aura Biosciences NASDAQ:AURA

Climb Bio NASDAQ:CLYM

Monopar Therapeutics NASDAQ:MNPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, MNPR, CLYM, and AURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, MNPR, CLYM, and AURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, MNPR, CLYM, and AURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, MNPR, CLYM, and AURA Company Descriptions

Alector NASDAQ:ALEC

Aura Biosciences NASDAQ:AURA

Climb Bio NASDAQ:CLYM

Monopar Therapeutics NASDAQ:MNPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools